Demetrios N Nicolaides
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Demetrios N Nicolaides has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dimitra Hadjipavlou-Litina
Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Ioanna Sigala
Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Konstantinos Eleutherios Litinas
Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Anastasia Maria Antonaki
Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece, Greece
1 shared publication - Catherine Gabriel
Environmental Engineering Laboratory, Department of Chemical Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
1 shared publication Daman R Gautam
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Preprints.org
A DBU-Catalyzed Rearrangement of 4-Hydroxy-3-Coumarinylchalcones to δ-Valerolactone-Fused Coumarins
The reaction of 4-hydroxy-3-coumarinylchalcone with acetylacetone in the presence of base was expected to result in Michael adduct. During this reaction in the presence of catalytic amount of DBU a rearrangement led to δ-valerolactone [3,4]-fused coumarin. The outcome of this rearrangement was almost the same in the presence or absence of active methylene compounds. Preliminary screening tests of the synthesized derivatives for LOX (lipoxygenase) inhibition activity and anticancer activity were performed.
- 9 November 2026
- Published by MDPI AG in Preprints.org
Open AccessA DBU-Catalyzed Rearrangement of 4-Hydroxy-3-Coumarinylchalcones to δ-Valerolactone-Fused Coumarins
The reaction of 4-hydroxy-3-coumarinylchalcone with acetylacetone in the presence of base was expected to result in Michael adduct. During this reaction in the presence of catalytic amount of DBU a rearrangement led to δ-valerolactone [3,4]-fused coumarin. The outcome of this rearrangement was almost the same in the presence or absence of active methylene compounds. Preliminary screening tests of the synthesized derivatives for LOX (lipoxygenase) inhibition activity and anticancer activity were performed.
- Open Access
- 6 March 2025
- Published by MDPI AG in Preprints.org
Synthesis of Coumarin-Isoxazole-Pyridine Hybrids with Possible Biological Activity [1]
The 1,3 -dipolar cycloaddition reaction of nitrile oxides, prepared in situ from pyridine aldehyde oximes, with propargyloxy- or propargylaminocoumarins afforded the corresponding new 3,5-disubstituted isoxazoles in moderate to good yields. As oxidants for the formation of nitrile oxides utilized (diacetoxyiodo)benzene (PIDA) at room temperature or under microwave irradiation or tert-butyl nitrite (TBN) under reflux. Preliminary in vitro screening tests for some biological activities of the new compounds have been performed. Compounds 12b and 13a are potent LOX inhibitors with IC50 5 μΜ and 10 μΜ, respectively, while hybrids 12b and 13a exhibit moderate to low anticancer activities on Hela, HT-29, and H1437 cancer cells.
- 6 March 2025
- Published by MDPI AG in Preprints.org
Open AccessSynthesis of Coumarin-Isoxazole-Pyridine Hybrids with Possible Biological Activity [1]
The 1,3 -dipolar cycloaddition reaction of nitrile oxides, prepared in situ from pyridine aldehyde oximes, with propargyloxy- or propargylaminocoumarins afforded the corresponding new 3,5-disubstituted isoxazoles in moderate to good yields. As oxidants for the formation of nitrile oxides utilized (diacetoxyiodo)benzene (PIDA) at room temperature or under microwave irradiation or tert-butyl nitrite (TBN) under reflux. Preliminary in vitro screening tests for some biological activities of the new compounds have been performed. Compounds 12b and 13a are potent LOX inhibitors with IC50 5 μΜ and 10 μΜ, respectively, while hybrids 12b and 13a exhibit moderate to low anticancer activities on Hela, HT-29, and H1437 cancer cells.
- 1 April 2004
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 39 (4) , 323-332
Synthesis and evaluation of the antioxidant and antiinflammatory activities of some benzo[l]khellactone derivatives and analogues
- 1 April 2004
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 39 (4) , 323-332
Synthesis and evaluation of the antioxidant and antiinflammatory activities of some benzo[l]khellactone derivatives and analogues